CA14 (carbonic anhydrase 14) is a transmembrane enzyme that catalyzes the reversible hydration of carbon dioxide 1. The protein contains 337 amino acids with a molecular mass of 37.6 kDa and shows 29-46% similarity to other active carbonic anhydrase isozymes, with highest similarity to CA XII 1. CA14 possesses hydrophobic segments at both termini for signal sequence and transmembrane domain localization, exhibits low catalytic activity, and is sensitive to acetazolamide but not sulfonamide 1. The gene is located on chromosome 1 and demonstrates tissue-specific expression patterns, with strong signals in brain regions, heart, liver, and skeletal muscle, contrasting with CA XII's expression profile 1. Recent proteomic studies have identified CA14 as a potential therapeutic target for multiple conditions. It shows associations with schizophrenia through drug repurposing analyses 2, mediates relationships between sleep patterns and chr1 diseases 3, and represents a novel drug target candidate for chr1 widespread pain treatment 4. Mendelian randomization analyses suggest CA14 levels may causally influence hippocampal volume and stroke risk 5, indicating its broader physiological significance beyond basic carbonic anhydrase function in neurological and metabolic processes.